Sponsors (6)
The resolution raises visibility of rare-disease needs and points to federal programs that could speed therapy development, but it provides no immediate funding or legal changes and could raise expectations or lead to policy choices that keep costs high.
People with rare diseases would gain greater recognition of their needs, increasing the likelihood that research and policy attention will be directed to them.
Patients and health systems could benefit over time if highlighted NIH and FDA programs lead to faster development and approval of new therapies.
Families and patients facing high costs could gain justification for future financial-relief or access measures because the findings explicitly cite financing and access challenges.
Patients with rare diseases will not see immediate funding, legal changes, or cost relief because the resolution is a findings statement without direct policy or funding authority.
If the findings lead to stronger drug-development incentives (e.g., extended exclusivity), patients and taxpayers could continue to face high drug prices.
Patients and families may experience frustration if heightened public attention raises expectations for immediate help that the resolution does not deliver.
Based on analysis of 2 sections of legislative text.
Expresses congressional findings about rare diseases, defines "rare disease," cites prevalence and treatment gaps, and recognizes the Orphan Drug Act anniversary and Rare Disease Day.
Introduced February 26, 2026 by John A. Barrasso · Last progress February 26, 2026
Recognizes and records congressional findings about rare diseases in the United States, including a definition of "rare disease," prevalence estimates, treatment gaps, and observances tied to the Orphan Drug Act and Rare Disease Day. It highlights the roles of federal research and regulatory agencies in supporting rare disease work but does not create new programs or appropriate funds. States that a rare disease is one affecting fewer than 200,000 people in the U.S., that over 30 million Americans live with one or more of more than 10,000 known rare diseases, that children make up a substantial share of those affected, and that about 95% of rare diseases lack an FDA‑approved treatment. The text also notes NIH research support, FDA programs for rare diseases, and the upcoming 43rd anniversary of the Orphan Drug Act and observance of Rare Disease Day.